News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
65,367 Results
Type
Article (4856)
Company Profile (5)
Press Release (60506)
Multimedia
Podcasts (62)
Webinars (3)
Section
Business (18620)
Career Advice (184)
Deals (2928)
Drug Delivery (14)
Drug Development (10709)
Employer Resources (26)
FDA (1859)
Job Trends (1920)
News (34032)
Policy (2942)
Tag
Academia (344)
Accelerated approval (3)
Adcomms (1)
Allergies (10)
Alliances (4242)
ALS (25)
Alzheimer's disease (278)
Antibody-drug conjugate (ADC) (23)
Approvals (1838)
Artificial intelligence (26)
Autoimmune disease (4)
Automation (3)
Bankruptcy (23)
Best Places to Work (1625)
BIOSECURE Act (3)
Biosimilars (8)
Biotechnology (5)
Bladder cancer (8)
Brain cancer (5)
Breast cancer (49)
Cancer (358)
Cardiovascular disease (31)
Career advice (144)
CAR-T (22)
Cell therapy (63)
Cervical cancer (3)
Clinical research (8852)
Collaboration (65)
Company closure (1)
Compensation (37)
Complete response letters (2)
COVID-19 (275)
CRISPR (9)
C-suite (29)
Cystic fibrosis (12)
Data (317)
Depression (11)
Diabetes (24)
Diagnostics (637)
Digital health (2)
Diversity, equity & inclusion (11)
Drug discovery (16)
Drug pricing (6)
Drug shortages (2)
Duchenne muscular dystrophy (31)
Earnings (6181)
Editorial (15)
Employer branding (3)
Employer resources (21)
Events (11565)
Executive appointments (85)
FDA (2003)
Funding (92)
Gene editing (14)
Generative AI (3)
Gene therapy (42)
GLP-1 (104)
Government (424)
Grass and pollen (1)
Guidances (10)
Healthcare (1964)
Huntington's disease (6)
IgA nephropathy (3)
Immunology and inflammation (14)
Indications (1)
Infectious disease (290)
Inflammatory bowel disease (9)
Inflation Reduction Act (1)
Influenza (5)
Intellectual property (11)
Interviews (45)
IPO (1367)
IRA (4)
Job creations (376)
Job search strategy (135)
Kidney cancer (2)
Labor market (1)
Layoffs (46)
Leadership (2)
Legal (635)
Liver cancer (12)
Lung cancer (29)
Lymphoma (37)
Management (5)
Manufacturing (36)
MASH (12)
Medical device (1207)
Medtech (1207)
Mergers & acquisitions (1597)
Metabolic disorders (88)
Multiple sclerosis (7)
NASH (2)
Neurodegenerative disease (20)
Neuropsychiatric disorders (7)
Neuroscience (381)
NextGen: Class of 2025 (749)
Non-profit (550)
Obesity (52)
Opinion (22)
Ovarian cancer (11)
Pain (14)
Pancreatic cancer (14)
Parkinson's disease (24)
Partnered (1)
Patents (29)
Patient recruitment (19)
Peanut (5)
People (7186)
Pharmaceutical (3)
Pharmacy benefit managers (1)
Phase I (2521)
Phase II (3847)
Phase III (3248)
Pipeline (153)
Policy (40)
Postmarket research (340)
Preclinical (950)
Prostate cancer (43)
Psychedelics (17)
Radiopharmaceuticals (45)
Rare diseases (37)
Real estate (472)
Recruiting (10)
Regulatory (2128)
Reports (1)
Research institute (280)
Resumes & cover letters (30)
Rett syndrome (4)
RNA editing (1)
RSV (4)
Schizophrenia (21)
Series A (22)
Series B (5)
Sickle cell disease (3)
Special edition (7)
Spinal muscular atrophy (7)
Sponsored (3)
Startups (370)
Stomach cancer (1)
Supply chain (2)
Tariffs (6)
The Weekly (61)
Vaccines (95)
Venture capitalists (5)
Weight loss (24)
Date
Today (10)
Last 7 days (100)
Last 30 days (328)
Last 365 days (3472)
2025 (1239)
2024 (3828)
2023 (4686)
2022 (5410)
2021 (6276)
2020 (5726)
2019 (5134)
2018 (3808)
2017 (3174)
2016 (2894)
2015 (4020)
2014 (2754)
2013 (1757)
2012 (1909)
2011 (2000)
2010 (1754)
Location
Africa (88)
Alabama (2)
Alaska (3)
Arizona (8)
Arkansas (1)
Asia (2756)
Australia (801)
California (683)
Canada (248)
China (40)
Colorado (22)
Connecticut (26)
Delaware (45)
Europe (8991)
Florida (109)
Georgia (12)
Idaho (5)
Illinois (50)
India (1)
Indiana (46)
Iowa (3)
Japan (19)
Kansas (6)
Kentucky (7)
Louisiana (1)
Maine (5)
Maryland (115)
Massachusetts (540)
Michigan (7)
Minnesota (48)
Missouri (11)
Montana (4)
Nevada (2)
New Hampshire (5)
New Jersey (214)
New Mexico (5)
New York (255)
North Carolina (62)
North Dakota (2)
Northern California (316)
Ohio (14)
Oklahoma (4)
Oregon (2)
Pennsylvania (167)
Puerto Rico (8)
Rhode Island (7)
South America (95)
South Carolina (1)
Southern California (224)
Tennessee (10)
Texas (59)
United States (2574)
Utah (4)
Virginia (9)
Washington D.C. (3)
Washington State (43)
Wisconsin (9)
65,367 Results for "erasmus mc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
First procedure in Netherlands with NaoTrac surgical navigation robot is performed at Erasmus MC Rotterdam
July 17, 2024
·
2 min read
Drug Development
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
AIM ImmunoTech Inc. today announced that it has received authorization from the Erasmus Medical Center (“Erasmus MC”) Ethics Committee to open a European site for the ongoing Phase 2 study (“AMP-270”) of Ampligen as a therapy for locally advanced pancreatic cancer.
January 24, 2024
·
2 min read
Press Releases
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
March 28, 2025
·
6 min read
Press Releases
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
April 17, 2025
·
6 min read
Press Releases
Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
March 26, 2025
·
6 min read
Press Releases
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
February 5, 2025
·
4 min read
Press Releases
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
April 1, 2025
·
9 min read
Policy
MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy
MC2 Therapeutics confirms it has received positive feedback from a pre-Investigational New Drug meeting with the US Food and Drug Administration with respect to its first-in-class, oral drug candidate MC2-32 for the treatment of Hidradenitis Suppurativa.
May 13, 2024
·
5 min read
Press Releases
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
February 6, 2025
·
5 min read
Lone Star Bio
Saranas Reveals Groundbreaking SAFE-MCS Study Results at CRT 2024
Saranas, Inc. announced today the compelling results of SAFE-MCS, a multi-center clinical study evaluating the safety of complex high-risk percutaneous coronary intervention (PCI) using mechanical circulatory support (MCS) and surveillance with the Early Bird ® Bleed Monitoring System (EBBMS).
March 11, 2024
·
4 min read
1 of 6,537
Next
